nach oben

Zeitschrift für Gerontologie und Geriatrie

28.11.2019 | Original Contributions

Rapamycin could increase the effects of melatonin against age-dependent bone loss

verfasst von: Zhou-Shan Tao, Han-Li Lu, Neng-Feng Ma, Rou-Tian Zhang, Yang Li, Min Yang, Hong-Guang Xu

Erschienen in: Zeitschrift für Gerontologie und Geriatrie

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have demonstrated the beneficial effect of melatonin (MEL) on bone tissue and bone metabolism. Rapamycin (RAP) promotes osteoblast proliferation and inhibits osteoclast proliferation, and positively affects bone regeneration; however, reports about effects of RAP on bone loss for aged female rats with MEL administration are limited. This study investigated the impact of treatment with RAP on bone loss for aged female rats with MEL administration. Female Sprague-Dawley rats weighing approximately 520 g were randomly divided into 3 groups of 10: group CON, group MEL and group MEL + RAP and received saline, MEL, RAP plus MEL treatment until death at 12 weeks, respectively. The results of maintaining bone mass and bone strength with RAP plus MEL administration were evaluated by histology, microcomputerized tomography (Micro-CT), gene expression analysis and biomechanical testing. Results from this study indicated that MEL + RAP had stronger effects on the prevention and treatment of osteoporosis than MEL administration. Administration of MEL + RAP produced the strongest effects on bone parameters and strength for distal femurs and regulation of OPG/RANKL signalling pathway-related gene expression. These results seemed to indicate that RAP could increase the effects of MEL on age-dependent bone loss.

Birkhäuser M (2012) Selective Estrogen Receptor Modulators (SERMs) for prevention and treatment of postmenopausal osteoporosis. Ther Umsch 69(3):163–172CrossRef

Deselm CJ, Zou W, Teitelbaum SL (2012) Halofuginone prevents estrogen-deficient osteoporosis in mice. J Cell Biochem 113(10):3086–3092CrossRef

Lou S, Lv H, Li Z, Zhang L, Tang P (2018) Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials. Bmj Open 8(3):e15187CrossRef

Qin S, Zhang Q, Zhang L (2017) Effect of OPG gene mutation on protein expression and biological activity in osteoporosis. Exp Ther Med 14(2):1475–1480CrossRef

Tabatabaeimalazy O, Salari P, Khashayar P, Larijani B (2017) New horizons in treatment of osteoporosis. Daru 25(1):2CrossRef

Liu J, Zhong R, Wei X, Liu H, Eisenegger C, Zhou X (2017) Melatonin increases reactive aggression in humans. Psychopharmacology 234(19):2971–2978CrossRef

Hardeland R, Madrid JA, Tan DX, Reiter RJ (2012) Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 52(2):139–166CrossRef

Salido EM, Melina B, Andrea DL, Mónica C, María IKS, Damián D et al (2013) Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. J Pineal Res 54(2):179–189CrossRef

María Piedad RF, Luis JCG, Arcesio RDR, Bruno N, Guillermo PZ, David PA et al (2013) Melatonin promotes angiogenesis during repair of bone defects: a radiological and histomorphometric study in rabbit tibiae. Clin Oral Invest 17(1):147–158CrossRef

10.

Oktem G, Uslu S, Vatansever SH, Aktug H, Yurtseven ME, Uysal A (2006) Evaluation of the relationship between inducible nitric oxide synthase (iNOS) activity and effects of melatonin in experimental osteoporosis in the rat. Surg Radiol Anat 28(2):157–162CrossRef

11.

Mizushima N (2007) Autophagy: process and function. Genes Dev. https://doi.org/10.1101/gad.1599207CrossRefPubMed

12.

Brinda R, Coralie V, Zdenek B, Davies JE, Shouqing L, Oroz LG et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585–595CrossRef

13.

Luo D, Ren H, Li T, Lian K, Lin D (2015) Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. Osteoporos Int 27(3):1–9

14.

Luo D, Ren H, Li T, Lian K, Lin D (2016) Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. Osteoporos Int 27(3):1093–1101. https://doi.org/10.1007/s00198-015-3325-5CrossRefPubMed

15.

Acikan I et al (2018) Systemic melatonin application increases bone formation in mandibular distraction osteogenesis. Braz Oral Res 32:e85CrossRef

16.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J et al (2010) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578–588CrossRef

17.

Tao ZS, Lv YX, Cui W, Huang ZL, Tu KK, Zhou Q et al (2016) Effect of teriparatide on repair of femoral metaphyseal defect in ovariectomized rats. Z Gerontol Geriatr 49(5):423–428. https://doi.org/10.1007/s00391-015-0949-1CrossRefPubMed

18.

Tao ZS, Qiang Z, Tu KK, Huang ZL, Xu HM, Sun T et al (2015) Treatment study of distal femur for parathyroid hormone (1–34) and beta-tricalcium phosphate on bone formation in critical size defects in rats. J Biomater Appl 30(4):484–491. https://doi.org/10.1177/0885328215592854CrossRefPubMed

19.

Chen L, Tao ZS, Chen H, Zhou K, Zhou DS (2017) Combined treatment with alendronate and Drynaria rhizome extracts: effect on fracture healing in osteoporotic rats. Z Gerontol Geriatr. https://doi.org/10.1007/s00391-017-1326-zCrossRefPubMed

20.

Tao ZS, Zhou WS, Wu XJ, Zhang X, Wang L, Xie JB et al (2019) Prevention of ovariectomy-induced osteoporosis in rats: comparative study of zoledronic acid, parathyroid hormone (1–34) and strontium ranelate. Z Gerontol Geriatr 52(2):139–147. https://doi.org/10.1007/s00391-018-1376-xCrossRefPubMed

21.

Fabien W, Claire P, Laurent L, Sylvie M, Marie-Jeanne D, Patrice L et al (2013) The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem 288(9):6542–6551CrossRef

22.

Tao ZS et al (2019) Local administration of aspirin with β‑tricalcium phosphate/poly-lactic-co-glycolic acid (β-TCP/PLGA) could enhance osteoporotic bone regeneration. J Bone Miner Metab. https://doi.org/10.1007/s00774-019-01008-wCrossRefPubMed

23.

Koyama H, Nakade O, Takada Y, Kaku T, Lau K‑HW (2010) Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 17(7):1219–1229CrossRef

24.

Shalini S, Radio NM, Kotlarczyk MP, Chien-Tsun C, Yau-Huei W, Ralf J et al (2011) Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res 50(3):222–238

25.

Kotlarczyk MP, Lassila HC, O’Neil CK, D’Amico F, Enderby LT, Witt-Enderby PA et al (2012) Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res 52(4):414–426CrossRef

26.

Sailaja Devi MM, Suresh Y, Das UN (2010) Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin. J Pineal Res 29(2:108–115

27.

Palin LP, Polo TOB, Batista FRDS, Garcia IR, Rossi AC, Freire A et al (2018) Daily melatonin administration improves osseointegration in pinealectomized rats. J Appl Oral Sci. https://doi.org/10.1590/1678-7757-2017-0470CrossRefPubMedPubMedCentral

28.

Guardia J et al (2011) Evaluation of effects of topic melatonin on implant surface at 5 and 8 weeks in beagle dogs. Clin Implant Dent Relat Res 13(4):262–268CrossRef

29.

Yilmaz H et al (2018) Antioxidant role of melatonin against nicotine’s teratogenic effects on embryonic bone development. Iran J Basic Med Sci 21(8):787–793PubMedPubMedCentral

30.

Nakade O, Koyama H, Ariji H, Yajima A, Kaku T (2010) Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 27(2):106–110CrossRef

31.

Shen G, Ren H, Qiu T, Zhang Z, Zhao W, Yu X et al (2017) Mammalian target of rapamycin as a therapeutic target in osteoporosis. J Cell Physiol. https://doi.org/10.1002/jcp.26161CrossRefPubMed

32.

Lingling X, Xiangwei W, Lijuan P, Michael L, Clifford JR, Tao Q et al (2012) Matrix IGF‑1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18(7):1095–1101CrossRef

33.

Jianquan C, Xiaolin T, Emel E, Kyu SJ, Congxin L, Jeffrey MA et al (2014) WNT7B promotes bone formation in part through mTORC1. PLoS Genet 10(1):e1004145CrossRef

34.

Lim J et al (2016) Dual function of Bmpr1a signaling in restricting preosteoblast proliferation and stimulating osteoblast activity in mouse. Development 143(2):339CrossRef

35.

Liu Q, Liu C, Yang Y, Yang H, Chen J (2018) Osteocyte-intrinsic mTORC1 signaling restrains trabecular bone accrual in mice. J Cell Biochem 119(11):8743–8749. https://doi.org/10.1002/jcb.27470CrossRefPubMed

36.

Dai Q, Han Y, Xie F, Ma X, Xu Z, Liu X et al (2018) A RANKL-based osteoclast culture assay of mouse bone marrow to investigate the role of mTORC1 in osteoclast formation. J Vis Exp. https://doi.org/10.3791/56468CrossRefPubMedPubMedCentral

37.

Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM et al (2010) Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 19(4):557–568CrossRef

38.

Darcy A, Meltzer M, Miller J, Lee S, Chappell S, Donck KV et al (2012) A novel library screen identifies immunosuppressors that promote osteoblast differentiation. Bone 50(6):1294–1303CrossRef

Titel: Rapamycin could increase the effects of melatonin against age-dependent bone loss
verfasst von: Zhou-Shan Tao
Han-Li Lu
Neng-Feng Ma
Rou-Tian Zhang
Yang Li
Min Yang
Hong-Guang Xu
Publikationsdatum: 28.11.2019
Verlag: Springer Medizin
Erschienen in: Zeitschrift für Gerontologie und Geriatrie
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI: https://doi.org/10.1007/s00391-019-01659-4

Springerpflege

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten